Cargando…

Targeting IL-4 for the Treatment of Atopic Dermatitis

Atopic dermatitis (AD) is an immune-mediated inflammatory skin disease characterized by a predominant type 2 immune response. Type 2 immunity is driven by multiple cytokines, including interleukin (IL)‑4 and IL-13 that are considered central to AD pathogenesis and key therapeutic targets. The dual i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chiricozzi, Andrea, Maurelli, Martina, Peris, Ketty, Girolomoni, Giampiero
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7532907/ https://www.ncbi.nlm.nih.gov/pubmed/33062619 http://dx.doi.org/10.2147/ITT.S260370

Ejemplares similares

Overview of Atopic Dermatitis in Different Ethnic Groups
por: Chiricozzi, Andrea, et al.
Publicado: (2023)

Novel Therapeutic Strategies in the Topical Treatment of Atopic Dermatitis
por: Pinto, Lorenzo Maria, et al.
Publicado: (2022)

Flare management in atopic dermatitis: from definition to treatment
por: Girolomoni, Giampiero, et al.
Publicado: (2022)

Prevalence of Non-Alcoholic Fatty Liver Disease in Adult Individuals with Moderate-to-Severe Atopic Dermatitis
por: Maurelli, Martina, et al.
Publicado: (2023)

Pruritus as a Distinctive Feature of Type 2 Inflammation
por: Garcovich, Simone, et al.
Publicado: (2021)

The role of insomnia in the vulnerability to depressive and anxiety symptoms in atopic dermatitis adult patients
por: Salfi, Federico, et al.
Publicado: (2023)

Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapy
por: D’Erme, Angelo Massimiliano, et al.
Publicado: (2017)

National Information Campaign Revealed Disease Characteristic and Burden in Adult Patients Suffering from Atopic Dermatitis
por: Gori, Niccolò, et al.
Publicado: (2022)

Nomenclature and clinical phenotypes of atopic dermatitis
por: Girolomoni, Giampiero, et al.
Publicado: (2021)

The Risk of COVID-19 Pandemic in Patients with Moderate to Severe Plaque Psoriasis Receiving Systemic Treatments
por: Gisondi, Paolo, et al.
Publicado: (2020)

Advanced Glycation End Products and Psoriasis
por: Maurelli, Martina, et al.
Publicado: (2023)

The IL-4/-13 Axis and Its Blocking in the Treatment of Atopic Dermatitis
por: Pappa, Georgia, et al.
Publicado: (2022)

Effectiveness and Safety of Upadacitinib in the Treatment of Moderate-Severe Atopic Dermatitis: A Multicentric, Prospective, Real-World, Cohort Study
por: Chiricozzi, Andrea, et al.
Publicado: (2022)

Shedding Light on Novel Pathogenic and Therapeutic Aspects Related to Immune-Mediated Skin Diseases
por: Chiricozzi, Andrea, et al.
Publicado: (2023)

Assessing patients’ characteristics and treatment patterns among children with atopic dermatitis
por: Geat, Davide, et al.
Publicado: (2021)

Selective IL-13 inhibitors for the treatment of atopic dermatitis
por: Gonçalves, Francisca, et al.
Publicado: (2021)

The Treat-to-Target Project in Atopic Dermatitis: One Year On
por: DE BRUIN-WELLER, Marjolein, et al.
Publicado: (2023)

Cutaneous Adverse Reactions Associated with SARS-CoV-2 Vaccines
por: Bellinato, Francesco, et al.
Publicado: (2021)

Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation
por: Chiricozzi, Andrea, et al.
Publicado: (2023)

Immune Response to Vaccination in Patients with Psoriasis Treated with Systemic Therapies
por: Chiricozzi, Andrea, et al.
Publicado: (2020)

IL-17 Inhibition: A Valid Therapeutic Strategy in the Management of Hidradenitis Suppurativa
por: Malvaso, Dalma, et al.
Publicado: (2023)

Correction to: Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation
por: Chiricozzi, Andrea, et al.
Publicado: (2023)

Annually Recurring Erythema Annulare Centrifugum: A New Case Series with Review of the Literature
por: Maurelli, Martina, et al.
Publicado: (2021)

Uncommon Non-Infectious Annular Dermatoses
por: Maurelli, Martina, et al.
Publicado: (2022)

Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential
por: Chiricozzi, Andrea, et al.
Publicado: (2019)

The Significance of IL-36 Hyperactivation and IL-36R Targeting in Psoriasis
por: Madonna, Stefania, et al.
Publicado: (2019)

Targeting Interleukin 13 for the Treatment of Atopic Dermatitis
por: Lytvyn, Yuliya, et al.
Publicado: (2023)

Novel Therapeutic Targets for the Treatment of Atopic Dermatitis
por: Tsuji, Gaku, et al.
Publicado: (2023)

Biological Treatments in Atopic Dermatitis
por: Montes-Torres, Andrea, et al.
Publicado: (2015)

Netherton syndrome plus atopic dermatitis: Two new genetic mutations in the same patient
por: Moar, Agata, et al.
Publicado: (2021)

Blockage of the IL-31 Pathway as a Potential Target Therapy for Atopic Dermatitis
por: Orfali, Raquel Leao, et al.
Publicado: (2023)

Advanced Glycation End Products in the Pathogenesis of Psoriasis
por: Papagrigoraki, Anastasia, et al.
Publicado: (2017)

Association between short-term exposure to environmental air pollution and atopic dermatitis flare in patients treated with dupilumab
por: Bellinato, Francesco, et al.
Publicado: (2023)

Amicrobial Pustulosis of the Folds: Report of Three New Cases
por: Bellinato, Francesco, et al.
Publicado: (2020)

Difamilast for the treatment of atopic dermatitis
por: Freitas, Egídio, et al.
Publicado: (2023)

Atopic dermatitis in adolescence
por: Ricci, Giampaolo, et al.
Publicado: (2011)

Atopic dermatitis
por: Galli, Elena, et al.
Publicado: (2020)

Atopic dermatitis
por: Watson, Wade, et al.
Publicado: (2011)

Atopic dermatitis
por: Kapur, Sandeep, et al.
Publicado: (2018)

Contact allergy in children with and without atopic dermatitis: An Italian multicentre study
por: Bonamonte, Domenico, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jhndrn88taihs3gtsnihnmvq13